Drug Trial Radar · NCT03112044
Lung Transplant HCV, Pilot Study
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
26
Actual
Start
Sep 19, 2017
Primary completion
Jan 2, 2020
Study completion May 31, 2027
Sponsor
- Lead sponsor
- University Health Network, TorontoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gilead Sciences
- First posted
- Apr 13, 2017
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study HCV negative recipients will be transplanted with HCV positive lungs. Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus. Patients will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs. It is planned to enroll 20 patients from the Lung transplant wait list in this study. Patients will be actively followed for 6 months including HCV PCR tests and then for up for 5 years to look for evidence of HCV infection and any liver or extra-hepatic complications, as well as standard post-transplant complications. This will be a single center pilot study.
Conditions
- Lung Transplant Infection
- Hepatitis C
Interventions
Sofosbuvir-velpatasvir (400 mg/100 mg)Drug
Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
Ex Vivo Lung Perfusion (EVLP)Device
Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of transplantation from HCV positive donors to HCV negative recipientsTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Health Network Toronto General Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.